Featured Research

from universities, journals, and other organizations

Antibiotic Linked To Newborns' Intestinal Disorder

Date:
October 2, 2001
Source:
Indiana University
Summary:
An Indiana University School of Medicine study has confirmed a linkage between erythromycin, one of the most commonly prescribed antibiotics, and the subsequent development of pyloric stenosis, a condition that affects one in 500 newborns. The study appears in the current issue of the Journal of Pediatrics.

An Indiana University School of Medicine study has confirmed a linkage between erythromycin, one of the most commonly prescribed antibiotics, and the subsequent development of pyloric stenosis, a condition that affects one in 500 newborns. The study appears in the current issue of the Journal of Pediatrics.

Pyloric stenosis, which usually occurs in the first or second month of life, is a blockage of the outlet of the stomach that causes projectile vomiting, leading to weight loss and dehydration. It is the most common indication for abdominal surgery in infancy.

"The link between erythromycin and pyloric stenosis is an important finding which will make a difference to the health of babies," said the study's principal investigator, Barbara E. Mahon, M.D., M.P.H., a clinical assistant professor of pediatrics at the IU School of Medicine.

Using clinical data extracted from the Regenstrief Medical Record System -- a comprehensive electronic medical records system that gathers and stores data including diagnoses, radiology and operative reports, pharmacy records, and physician observations -- the researchers studied 14, 876 babies born between June 1993 and December 1999. They found that if given erthromycin during the first two weeks of life, babies were 10.5 times more likely to develop pyloric stenosis than babies who were not given the antibiotic.

"This large scale study could only have been undertaken with the vast amount of data available in the Regenstrief system," said Dr. Mahon. Co-authors of the study are Marc Rosenman, M.D. a health services research fellow at the Regenstrief Institute for Healthcare ,and Martin Kleiman, M.D., Ryan White Professor of Pediatrics at the IU School of Medicine.

The newborns were given erthromycin by mouth in a 10-to-14 day course, usually because of maternal chlamydia at the time of delivery. Erythromycin has had a long history as a useful, safe, and generally well-tolerated drug, the researchers reported. However, as a result of their study they say that the antibiotic should be used only with prudence in the first two weeks of life.

The IU School of Medicine study also showed that babies who received an erythromycin eye ointment, a common treatment for conjunctivitis, did not have a higher risk of pyloric stenosis.


Story Source:

The above story is based on materials provided by Indiana University. Note: Materials may be edited for content and length.


Cite This Page:

Indiana University. "Antibiotic Linked To Newborns' Intestinal Disorder." ScienceDaily. ScienceDaily, 2 October 2001. <www.sciencedaily.com/releases/2001/10/011002065223.htm>.
Indiana University. (2001, October 2). Antibiotic Linked To Newborns' Intestinal Disorder. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2001/10/011002065223.htm
Indiana University. "Antibiotic Linked To Newborns' Intestinal Disorder." ScienceDaily. www.sciencedaily.com/releases/2001/10/011002065223.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins